Hosted on MSN1mon
Glox to develop precision antibiotics for cystic fibrosisGlox Therapeutics is set to receive a share of the £3m ($3.67m) Collaborative Discovery Programme (CDP) funding introduced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate. The ...
Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development of its novel precision antibiotics, helping to address the growing need for effective treatments to ...
Morningstar brands and products Company Portfolio ...
Glasgow, UK, 11 February 2025: Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced the appointment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results